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Hypertrophic cardiomyopathy (HCM) is an inherited cardiac disease with an autosomal dominant mode of transmission.
Comprehensive genetic screening of several genes frequently found mutated in HCM is recommended for ﬁrst-degree relatives of
HCMpatients.GenetictestingprovidesthemeanstoidentifythoseatriskofdevelopingHCMandtoinstitutemeasurestoprevent
sudden cardiac death (SCD). Here, we present an adoptee whose natural mother and maternal relatives were known be aﬄicted
with HCM and SCD. The proband was followed closely from age 6 to 17 years, revealing a natural history of the progression of
clinical ﬁndings associated with HCM. Genetic testing of the proband and her natural mother, who is aﬀected by HCM, revealed
that they were heterozygous for both the R719Q and T1513S variants in the cardiac beta-myosin heavy chain (MYH7)g e n e .T h e
proband’s ominous family history indicates that the combination of the R719Q and T1513S variants in cis may be a “malignant”
variant that imparts a poor prognosis in terms of the disease progression and SCD risk.
1.Introduction
Hypertrophic cardiomyopathy (HCM), characterized by
thickened ventricles, cardiomyocyte hypertrophy, and my-
oﬁbrillar disarray, is a relatively common inherited cardiac
condition, aﬀecting approximately 1 in 500 individuals.
HCM, which is the leading cause of sudden cardiac death
(SCD) in youth, causes signiﬁcant morbidity and mortality
in aﬀected individuals [1]. As a number of mutations in the
sarcomere genes have been causally linked to HCM, genetic
testing of ﬁrst-degree relatives of HCM patients is recom-
mended to identify those at increased risk for developing
HCM. One of the most frequent HCM susceptibility genes
is the cardiac beta-myosin heavy chain gene (MYH7), which
is mutated in approximately 15% to 30% of all HCM [1].
Speciﬁc mutations in MYH7 have also been found to be
associatedwithseveredisease,includinggreaterhypertrophy,
younger age at diagnosis, and worse prognosis [1, 2].
2.CaseReport
The proband, an adopted six-year-old girl, and her four-
year-old sister were brought to a pediatric cardiologist for
evaluation, largely at the insistence of the natural maternal
grandmother (MGM), who had maintained contact with
the adoptive parents. At the time of the initial evaluation,
the proband’s family history, obtained through the natu-
ral MGM, was notable for hypertrophic cardiomyopathy
(HCM) in her maternal uncle (diagnosed on autopsy
following SCD at age 15), maternal grandfather (s/p ICD for
HCM), and two maternal great aunts (SCD at age 16 and2 Cardiology Research and Practice
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Figure 1: Pedigree of the adoptee. The proband is highlighted by
the arrow. The proband carries two sequence variations within the
MYH7 (cardiac beta-myosin heavy chain gene): 2156G>A (R719Q)
change in exon 19 (marked by a shaded area on upper left hand
corner),and4537A>T(T1513S)onexon33(theshadedareaonthe
lower left hand corner). Cardiac hypertrophy is marked by shaded
area on upper right-hand corner). SCD: sudden cardiac death. ICD:
internal cardiac deﬁbrillator placed (dot).
36) (Figure 1). At the time of the maternal uncle’s death, the
cardiacstatusoftheproband’smotherwasdeemed“normal.”
On initial evaluation, the proband was asymptomatic with
a normal physical exam, a normal electrocardiogram (ECG)
and a normal echocardiogram. Given their signiﬁcant family
history for HCM, the proband and her sister were followed
at 1-2 year intervals.
At 8, 11, and 13 years, the proband was largely as-
ymptomatic. The electrocardiograms showed no evidence
of ST changes, left ventricular hypertrophy (LVH), or T-
wave changes. The echocardiograms were completely within
normal limits. She remained a very active child playing
soccer and basketball without any exercise intolerance. At 13
years, the proband experienced a syncopal episode lasting a
few minutes that was attributed to a vasovagal event. Her
ECG and Holter monitoring at the time did not show any
abnormalities.
At 14 years, the proband continued to be athletic and
denied any symptoms. Her physical exam and echocardio-
gram were normal. However, the proband’s ECG did show
nonspeciﬁc ST-T wave changes (Figure 2(a)). At this time,
genetic testing was discussed with her and her adopted
parents, but the family opted to defer testing.
At 15 years, the proband’s ECG showed right bundle
branch block, right posterior fascicular block, and Q waves
in the lateral and inferior leads (Figure 2(b)). Subsequent
cardiac evaluations, including an exercise stress test, echo,
and MRI, however, were normal, without any signs of
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Figure 2:EvolutionofECGintheproband.(a)Theproband’sECG
at age 14 years. It is notable for Q-waves in lateral and inferior leads
with nonspeciﬁc ST- and T-wave changes. (b) The proband’s ECG
at age 15 years. It is notable for right bundle branch block with left
posterior fascicular block, Q waves in lateral, and inferior leads.
myocardial ischemia or hypertrophy. The proband denied
any symptoms or exercise intolerance.
At 17 years, the proband’s echocardiogram showed very
mild concentric LVH (thickness 1.1cm, Z-Score of 2), with
evidence of diastolic dysfunction (maximal E:E’ ratio=12).
An exercise stress test did not reveal any evidence of ischemia
or ectopy, and Holter monitoring was unremarkable. At
this time, the proband was restricted from participating
in competitive athletics, and genetic testing was performed
(see below). An MRI performed two weeks later showed
normal overall left ventricular mass at 67g/m sq and normal
interventricular septal and posterior wall thickness, but also
revealed a prominent 2.7cm thickening of the anterior wall
at the base of the left ventricle (Figure 3).
The genetic testing, performed by the Harvard-Partners
Laboratory for Molecule Medicine (http://www.hpcgg.org/
LMM/), involved sequencing the coding regions and splice
sites of the genes encoding the sarcomeric proteins car-
diac alpha-actin (ACTC), cardiac myosin-binding protein
C( MYBPC3), cardiac beta-myosin heavy chain (MYH7),
myosin regulatory light chain (MYL2),cardiac myosin essen-
tial light chain (MYL3), cardiac troponin I (TNNI3), cardiac
troponin T2 (TNNT2), and tropomyosin 1 (TPM1). In addi-
tion, the genetic testing included sequencing the genes for
alpha-galactosidase A (GLA), lysosomal associated mem-
braneprotein2(LAMP2),andAMP-activatedproteinkinase,
gamma-2 subunit (PRKAG2), which are involved in storageCardiology Research and Practice 3
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Figure 3: Focal hypertrophy noted on the proband’s cardiac MRI. (a) 2-chamber end-diastole view. ∗marks the focal thickening (2.7cm,
thick × 1.8cm, length) of the anterior wall at the base of the left ventricle. (b) 4-chamber end-diastole view.
diseases that can lead to cardiac hypertrophy [3]. The
sequencing eﬀort revealed two variants in the MYH7 gene:
the proband was doubly heterozygous for a R719Q variant
(2156G>A in Exon19) as well as a T1513S variant (4537A>T
in Exon 33). The R179Q variant alone was likely to be
causativeforHCMasitmetthecriteriaforpathogenitybased
on segregation studies and frequency [2, 4–7]. However,
the signiﬁcance of the T1513S variant was unclear even
though it was detected in one additional HCM patient
tested by the reference lab (http:// www.hpcgg.org/LMM/)
and in one patient reported in the literature [2]. In both
of these prior cases, the T1513S variant was found in
combination with the R719Q variant. Given the rare but
recurrent presyncopal/syncopal complaints and signiﬁcant
family history of SCD, the proband received an internal
cardiac deﬁbrillator (ICD). The proband’s 15-year-old sister
was not found to have any genetic variants.
To determine the signiﬁcance of the MYH7 T1513S
variant, and to determine whether the two variants are
present in cis (on the same allele) or in trans (on diﬀerent
copies of the gene), we contacted the proband’s natural
birth mother. The natural mother (36 years old) was found
to have developed signiﬁcant hypertrophic cardiomyopathy
(IVS dimension of 2.7cm, with a resting LV outﬂow gradient
of 40mmHg) with debilitating heart failure symptoms. She
h a dr e c e i v e da nI C Da n dw a sa w a i t i n gs e p t a lm y o m e c t o m y .
The genetic test on the mother revealed that she too was a
heterozygote for both the R719Q and T1513S variants.
3. Discussion
Here, we present a case of a young adoptee with signiﬁcant
family history of HCM and sudden cardiac death who was
closely monitored from age 6 to 17. This close follow-up
revealed a pattern of natural history of HCM which may be
generalizable. Firstly, her ECG began to show subtle changes
as early as age 15, when her echocardiogram and MRI
were normal. Then, at age 17, her echocardiogram showed
diastolic dysfunction in the setting of minimal hypertrophy.
Interestingly, an MRI obtained just two weeks later showed
focal thickening in the anterior wall not previously seen by
echocardiogram.Theseobservationssuggestthattheappear-
ance of ECG changes and diastolic dysfunction predate gross
hypertrophy on echocardiogram, and that cardiac MRI is a
more sensitive modality to detect focal hypertrophy [8].
Theprobandandhermotherwerebothfoundtohavethe
R719Q and T1513S variants in the MYH7 gene, indicating
that the two variants are on the same copy of the gene. In the
onlypriorreportofthisvariantcombination,animplantable
cardioverter deﬁbrillator (ICD) was placed partly because of
signiﬁcant family of sudden cardiac death [2]. The proband
reported here also has a very signiﬁcant history of sudden
cardiac death and early mortality due to HCM. Therefore,
we suggest that the combination of the R719Q and T1513S
variants in cis may be a “malignant” variant that imparts
a poor prognosis in terms of the disease progression and
the SCD risk. In the previous studies, the R719Q mutation
was associated with divergent clinical presentations and
prognoses: from mild hypertrophy without incidence of
sudden death in a family of Hispanic origin [4]t oh i g h
incidence of sudden death in a Chinese family [6]. However,
the MYH7 gene’s exon 33, where the T1513S variant is
situated, was not sequenced in either study, so it is possible
that the Chinese family with the malignant phenotype
carried an additional mutation in cis, resembling the R719Q
and T1513S variant combination reported here.
This case is notable for the fact that the proband was
an adoptee whose adoptive parents have maintained contact
with the natural maternal grandmother. This was critical in
providing the ominous family history that compelled close
cardiac follow despite the lack of overt evidence of HCM for
many years. Finally, genetic testing of the aﬀected natural
mother provided the critical information establishing that
the two variants were on the same copy of the MYH7 gene.4 Cardiology Research and Practice
Thus, the proband has a 50% of chance of transmitting the
disease genotype to each of her children rather than a 100%
chance had the two variants been on separate chromosomes.
This case highlights the importance of the need for close
follow-up and comprehensive genetic evaluation of ﬁrst
degree relatives of patients with hypertrophic cardiomyopa-
thy.
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